The expectation is that each Designated Cancer Center will maintain their data within CTRP throughout the year.  For any questions/concerns, please reach out to the CTRO (NCICTRO@mail.nih.gov) and/or any other Cancer Centers as early in the process as possible.

CCSG Competing Type 2/Renewal Applications

CTRP-generated DT4 (PDF) version:  Used for CCSG Competing Type 2/Renewal applications (limited fields in support of the Competing Data Guide requirements for DT4) https://cancercenters.cancer.gov/GrantsFunding/DataGuide 

Submissions Requirements

Templates/File Name Recommendations

File Name and Email Template Recommendations:

CCSG Non-Competing RPPR Applications

Submissions Requirements

Templates/File Name Recommendations

File Name and Email Template Recommendations:


~-~-~-**EMAIL TEMPLATE TO BE CUSTOMIZED AND SENT BY CANCER CENTER**~-~-~-~
From: << Cancer Center >>
To: ccsgdata@mail.nih.gov
Cc: Cancer Center Administrator; Cancer Center Staff; NCIOCC Program Director (optional)

Subject: Cancer Center: Final DT4 Report FY20XX
Importance: High

Dear National Cancer Institute Office of Cancer Centers:

I am submitting the final CTRP-generated Data Table 4 (DT4) report for interventional trials and observational studies on behalf of the << Cancer Center >>. This report reflects Fiscal Year 20XX for the reporting period January 1, 20XX – December 31, 20XX.

This email includes a copy of the following documents for review:
Final << Cancer Center >> CTRP-Generated DT4 Report(s) (Interventional Trials and Observational Studies) with comments (Excel Version “supporting version with comments” and/or “Supplemental – Not on Report” tab)
Final << Cancer Center >> CCSG DT4 (Ancillary-Correlative studies) (using the CCSG DT4 template)

Do not hesitate to contact us if you have any immediate questions.

Regards,
From: << Cancer Center >>

This email, including attachments, may contain privileged and confidential information intended only for the use of the individual(s) named above. Dissemination, distribution, or copying of this message or its contents is subject to authorization by the sender. If you have received this message in error, please notify the sender and delete immediately.